Increased repetitive behaviours and prolactin responsivity to oral m-chlorophenylpiperazine in adults with autism spectrum disorders

International Journal of Neuropsychopharmacology

Volumn 7, Issue 3, 2004, Pages 249-254

  Novotny, Sherie ^a   Hollander, Eric ^a   Phillips, Ann ^a   Allen, Andrea ^a   Wasserman, Stacey ^a   Iyengar, Rupa ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Asperger's disorder; Autism; Obsessive compulsive behaviours; Oxytocin; Peptide

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; FENFLURAMINE; PROLACTIN; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR;

ADULT; ARTICLE; ASPERGER SYNDROME; AUTISM; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; STEREOTYPY;

ADOLESCENT; ADULT; ASPERGER SYNDROME; AUTISTIC DISORDER; BEHAVIOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PIPERAZINES; PROLACTIN; SEROTONIN AGONISTS; SOCIAL BEHAVIOR;

EID: 4444283450     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S146114570400433X     Document Type: Article

References (48)

1. Abramson RK, Wright HH, Carpenter R, Brennan W, Lumpuy O, Cole E, Young SR (1989). Elevated blood 5-HT in autistic probands and their first-degree relatives. Journal of Autism and Developmental Disorders 19, 397-407.
2. Aloi J, Insel T, Mueller E, Murphy D (1984). Neuroendocrine and behavioural effects of m-chlorphenylpiperazine administration in rhesus monkeys. Life Sciences 34, 1325-1331.
3. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
4. Charney D, Goodman W, Price L, Woods S, Rasmussen S, Heninger G (1988). Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Archives of General Psychiatry 45, 177-185.
5. Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, da Silva EA, Chugani HT (1997). Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Annals of Neurology 42, 666-669.
6. Cook E, Chourchesne R, Lord C, Cox N, Yan S, Lincoln A, Haas R, Courchesne E, Leventhal B (1997). Evidence of linkage between the serotonin transporter and autistic disorder. Molecular Psychiatry 2, 247-250.
7. Cook E, Leventhal B (1996). The serotonin system in autism. Current Opinions in Pediatrics 8, 348-354.
8. Cuccaro ML, Wright HH, Abramson RK, Marsteller FA, Valentine J (1993). Whole-blood serotonin and cognitive functioning in autistic individuals and their first-degree relatives. Journal of Neuropsychiatry and Clinical Neuroscience 5, 94-101.
9. De Villard R, Flachaire E, Laujin A, Maillet J, Revol O, Charles S, Mamelle JC, Renaud B, Quincy C (1991). Platelet serotonin concentration in children under 5 years of age. Pediatrie 46, 813-816.
10. Fiorella D, Rabin R, Winter J (1995). The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-cholorophenylpiperazine. Psychopharmacology 119, 222-230.
11. First M, Spitzer R, Gibbon M, Williams J (1995). Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition. Biometrics Research Department, New York, NY.
12. Frazer A, Daws L (1998). Serotonin transporter function in vivo: assesment by chronoamperometry. Annals of the Nezo York Academy of Sciences 861, 217-229.
13. Fuller RW, Snoddy HD, Mason NR, Owen JE (1981). Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology 20, 155-162.
14. Fuxe K, Ogren SO, Agnati LF, Benfenati F, Fredholm B, Andersson K, Zini I, Eneroth P (1983). Chronic antidepressant treatment and central 5-HT synapses. Neuropharmacology 22 (3 Special No.), 389-400.
15. Geller E, Ritvo E, Freeman B, Yuwiler A (1982). Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. New England Journal of Medicine 307, 165-169.
16. Gordon C, State R, Nelson J, Hamburger S, Rapoport J (1993). A double-blind comparison of clomiprarnine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry 50, 441-447.
17. Hamik A, Peroutka S (1989). 1-(m-chlorophenyl)piperazine (m-CPP) interactions with neurotransmitter receptors in the human brain. Biological Psychiatry 25, 569-575.
18. Hollander E, Cartwright C, Wong C, DeCaria C, DelGiudice-Asch G, Buchsbaum M, Aronowitz B (1998). A dimensional approach to the autism spectrum. CNS Spectrums. International Journal of Neuropsychiatric Medicine 3, 22-39.
19. Hollander E, DeCaria C, Nitescu A, Gully R, Suckow R, Cooper T, Gorman J, Klein D, Liebowitz M (1992). Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m- chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Archives of General Psychiatry 49, 21-28.
20. Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF (1990). Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Journal of Clinical Psychiatry 51, 119-23.
21. Hollander E, Novotny S, Allen A, Aronowitz B, DeCaria C (2000). The relationship between repetitive behaviours and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology 22, 163-167.
22. Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S (2003). Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 28, 193-198.
23. Hoshino Y, Tachibana R, Watanabe M, Murata S, Yokoyama F, Kaneko M, Yashima Y, Kumashiro H (1984). Serotonin metabolism and hypothalamic-pituitary function in children with infantile autism and minimal brain dysfunction. Japanese Journal of Psychiatry and Neurology 41, 228-235.
24. Invernizzi R, Berettera C, Garattini S, Samanin R (1986). D- and L-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. European Journal of Pharmacology 120, 9-15.
25. Klauck SM, Poustka F, Benner A, Lesch KP, Poustka A (1997). Serotonin transporter (5-HTT) gene variants associated with autism? Human Molecular Genetics 6, 2233-2238.
26. Leboyer M, Philippe A, Bouvard M, Guilloud-Bataille M, Bondoux D, Tabuteau F, Feingold J, Mouren-Simeoni MC, Launay JM (1999). Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biological Psychiatry 45, 158-163.
27. Leventhal BL, Cook Jr. EH, Morford M, Ravitz A, Freedman DX (1990). Relationships of whole blood serotonin and plasma norepinephrine within families. Journal of Autism and Developmental Disorders 20, 499-511.
28. Lord C, Rutter M, LeCouteur A (1994). Autism Diagnostic Interview - Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders 24, 659-685.
29. Maj J, Lewandowska A (1980). Central serotoninmimetic action of phenylpiperazines. Polish Journal of Pharmacology and Pharmacy 32, 495-504.
30. McBride PA, Anderson GM, Hertzig ME, Sweeney JA, Kream J, Cohen DJ, Mann JJ (1989). Serotonergic responsivity in male young adults with autistic disorder. Results of a pilot study. Archives of General Psychiatry 46, 213-221.
31. McDougle CJ, Kresch LE, Goodman WK, Naylor ST, Volkmar FR, Cohen DJ, Price LH. (1995). A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. American Journal of Psychiatry 152, 772-777.
32. McDougle C, Naylor S, Cohen D, Aghajanian G, Henninger G, Price L (1996b). Effects of tryptophan depletion in drug-free adults with autistic disorder. Archives of General Psychiatry 53, 993-1000.
33. McDougle D, Naylor S, Cohen D, Volkmar F, Heninger G, Price L (1996a). A double-blind, placebo controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry 53, 1001-1008.
34. Modahl C, Green L, Fein D, Morris M, Waterhouse L, Feinstein C, Levin H (1998). Plasma oxytocin levels in autistic children. Biological Psychiatry 43, 270-277.
35. Mueller EA, Murphy DL, Sunderland T (1985). Neuroendocrine effects of m-chlorphenylpiperazine, a serotonin agonist, in humans. Journal of Clinical Endocrinology and Metabolism 61, 1179-1184.
36. Mueller EA, Murphy DL, Sunderland T (1986). Further studies of the putative serotonm agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology (Berlin) 89, 388-391.
37. Novotny S, Hollander E, Allen A, Mosovich S, Aronowitz B, Cartwright C, DeCaria C, Dolgoff-Kaspar R (2000). Increased growth hormone response to sumatriptan challenge in adult autistic disorders. Psychiatry Research 44, 173-177.
38. Ogren S, Fuxe K, Agnati L (1985). The importance of brain serotonergic receptor mechanisms for the action of antidepressant drugs. Pharmacopsychiatry 18, 209-213.
39. Piven J, Tsai GC, Nehme E, Coyle JT, Chase GA, Folstein SE (1991). Platelet serotonin, a possible marker for familial autism. Journal of Autism and Developmental Disorders 21, 51-59.
40. Quattrone A, Schettini G, Annunziato L, Di Renzo G (1981). Pharmacological evidence of supersensitivity of central serotonergic receptors involved in the control of prolactin secretion. European Journal of Pharmacology 134, 851-855.
41. Rokosz-Pelc A, Antkiewicz-Michaluk L, Vetulani J (1980). 5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine. Journal of Pharmacy and Pharmacology 32, 220-222.
42. Schain R, Freedman D (1961). Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. Journal of Pediatrics 58, 315-320.
43. Silverstone PH, Cowen PJ (1994). The 5-HT3 antagonist, BRL 464470 does not attenuate m-chlorophenylpiparzine (m-CPP)-induced changes in human volunteers. Biological Psychiatry 36, 309-316.
44. Smith T, Suckow R (1985). Trazadone and m-chlorophenylpiperazine Concentration in brain and receptor activity in regions in the brain associated with anxiety. Neuropharmacology 24, 1067-1071.
45. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS (2001). 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. Journal of Neuroscience 21, 3572-3579.
46. Zhang Y, Damjanoska KJ, Carrasco GA, Dudas B, D'Souza DN, Tetzlaff J, Garcia F, Hanley NR, Scripathirathan K, Petersen BR, Gray TS, Battaglia G, Muma NA, Van de Kar LD (2002). Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI. Journal of Neuroscience 22, 9635-9642.
47. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL (1988). Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Archives of General Psychiatry 45, 167-172.
48. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987). Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Archives of General Psychiatry 44, 946-951.